

Jean-Pierre Pelletier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2361233/publications.pdf>

Version: 2024-02-01

243
papers

20,262
citations

8181

76
h-index

11607

135
g-index

245
all docs

245
docs citations

245
times ranked

14006
citing authors

#	ARTICLE	IF	CITATIONS
1	The relationship between knee loading during gait and cartilage thickness in nontraumatic and posttraumatic knee osteoarthritis. <i>Journal of Orthopaedic Research</i> , 2022, 40, 1778-1786.	2.3	2
2	An Open Debate on the Morphological Measurement Methodologies of the Infrapatellar Fat Pad to Determine Its Association with the Osteoarthritis Process. <i>Current Rheumatology Reports</i> , 2022, 24, 76-80.	4.7	2
3	Estrogenic impregnation alters pain expression: analysis through functional neuropeptidomics in a surgical rat model of osteoarthritis. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 703-715.	3.0	4
4	Risk factors associated with the occurrence of total knee arthroplasty in patients with knee osteoarthritis: a nested caseâ€“control study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210913.	2.7	1
5	A Machine Learning Model to Predict Knee Osteoarthritis Cartilage Volume Changes over Time Using Baseline Bone Curvature. <i>Biomedicines</i> , 2022, 10, 1247.	3.2	8
6	The association between change in bone marrow lesion size and change in tibiofemoral cartilage volume and knee symptoms. <i>Rheumatology</i> , 2021, 60, 2791-2800.	1.9	9
7	A warning machine learning algorithm for early knee osteoarthritis structural progressor patient screening. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2199325.	2.7	24
8	Associations of blood pressure and arterial stiffness with knee cartilage volume in patients with knee osteoarthritis. <i>Rheumatology</i> , 2021, 60, 4748-4754.	1.9	2
9	Osteoarthritis Research Society International (OARSI): Past, present and future. <i>Osteoarthritis and Cartilage Open</i> , 2021, 3, 100146.	2.0	1
10	Machine Learningâ€“Based Individualized Survival Prediction Model for Total Knee Replacement in Osteoarthritis: Data From the Osteoarthritis Initiative. <i>Arthritis Care and Research</i> , 2021, 73, 1518-1527.	3.4	21
11	Common Biochemical and Magnetic Resonance Imaging Biomarkers of Early Knee Osteoarthritis and of Exercise/Training in Athletes: A Narrative Review. <i>Diagnostics</i> , 2021, 11, 1488.	2.6	4
12	Clinical relevance of MRI knee abnormalities in Australian rules football players: a longitudinal study. <i>BMJ Open Sport and Exercise Medicine</i> , 2021, 7, e001097.	2.9	0
13	Associations of Joint Line Tenderness and Patellofemoral Grind With Longâ€“Term Knee Joint Outcomes: Data From the Osteoarthritis Initiative. <i>Arthritis Care and Research</i> , 2020, 72, 778-786.	3.4	3
14	The bulge sign â€“ a simple physical examination for identifying progressive knee osteoarthritis: data from the Osteoarthritis Initiative. <i>Rheumatology</i> , 2020, 59, 1288-1295.	1.9	5
15	Mesenchymal Stromal Cell Immunology for Efficient and Safe Treatment of Osteoarthritis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 567813.	3.7	21
16	Intra-articular corticosteroid knee injection induces a reduction in meniscal thickness with no treatment effect on cartilage volume: a caseâ€“control study. <i>Scientific Reports</i> , 2020, 10, 13789.	3.3	16
17	Identification of the most important features of knee osteoarthritis structural progressors using machine learning methods. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093346.	2.7	25
18	A continuous data driven translational model to evaluate effectiveness of population-level health interventions: case study, smoking ban in public places on hospital admissions for acute coronary events. <i>Journal of Translational Medicine</i> , 2020, 18, 466.	4.4	4

#	ARTICLE	IF	CITATIONS
19	Serum adipokines/related inflammatory factors and ratios as predictors of infrapatellar fat pad volume in osteoarthritis: Applying comprehensive machine learning approaches. <i>Scientific Reports</i> , 2020, 10, 9993.	3.3	13
20	An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis. <i>Rheumatology</i> , 2020, 59, 3858-3868.	1.9	26
21	A reliable time-series method for predicting arthritic disease outcomes: New step from regression toward a nonlinear artificial intelligence method. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 189, 105315.	4.7	12
22	Role of Lipocalin A Type Prostaglandin D Synthase in Experimental Osteoarthritis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1524-1533.	5.6	8
23	Effect of Intravenous Zoledronic Acid on Tibiofemoral Cartilage Volume Among Patients With Knee Osteoarthritis With Bone Marrow Lesions. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1456.	7.4	59
24	Viewpoint on Time Series and Interrupted Time Series Optimum Modeling for Predicting Arthritic Disease Outcomes. <i>Current Rheumatology Reports</i> , 2020, 22, 27.	4.7	3
25	In vivo protective effect of adiponin-deficiency on spontaneous knee osteoarthritis in aging mice. <i>Aging</i> , 2020, 12, 2880-2896.	3.1	8
26	L-PGDS deficiency accelerated the development of naturally occurring age-related osteoarthritis. <i>Aging</i> , 2020, 12, 24778-24797.	3.1	7
27	Response to Bio-optimized Curcuma longa extract is efficient on knee osteoarthritis pain: a double-blind multicenter randomized placebo controlled three-arm study. <i>Arthritis Research and Therapy</i> , 2020, 22, 22.	3.5	0
28	Activation of The Phosphatidylcholine to Lysophosphatidylcholine Pathway Is Associated with Osteoarthritis Knee Cartilage Volume Loss Over Time. <i>Scientific Reports</i> , 2019, 9, 9648.	3.3	34
29	Sensitivity of functional targeted neuropeptide evaluation in testing pregabalin analgesic efficacy in a rat model of osteoarthritis pain. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 723-733.	1.9	3
30	An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 337-350.	3.4	392
31	Knee effusion volume assessed by magnetic resonance imaging and progression of knee osteoarthritis: data from the Osteoarthritis Initiative. <i>Rheumatology</i> , 2019, 58, 246-253.	1.9	29
32	A new decision tree for diagnosis of osteoarthritis in primary care: international consensus of experts. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 19-30.	2.9	31
33	Machine-learning-based patient-specific prediction models for knee osteoarthritis. <i>Nature Reviews Rheumatology</i> , 2019, 15, 49-60.	8.0	119
34	Osteoarthritic pain model influences functional outcomes and spinal neuropeptidomics: A pilot study in female rats. <i>Canadian Journal of Veterinary Research</i> , 2019, 83, 133-141.	0.2	4
35	Diacerein-containing products: same risk of diarrhoea?. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 411-412.	2.9	12
36	In vivo effect of opticin deficiency in cartilage in a surgically induced mouse model of osteoarthritis. <i>Scientific Reports</i> , 2018, 8, 457.	3.3	8

#	ARTICLE	IF	CITATIONS
37	How Do MRI-Detected Subchondral Bone Marrow Lesions (BMLs) on Two Different MRI Sequences Correlate with Clinically Important Outcomes?. <i>Calcified Tissue International</i> , 2018, 103, 131-143.	3.1	3
38	Validity of Combining History Elements and Physical Examination Tests to Diagnose Patellofemoral Pain. <i>Archives of Physical Medicine and Rehabilitation</i> , 2018, 99, 607-614.e1.	0.9	15
39	Exploring determinants predicting response to intra-articular hyaluronic acid treatment in symptomatic knee osteoarthritis: 9-year follow-up data from the Osteoarthritis Initiative. <i>Arthritis Research and Therapy</i> , 2018, 20, 40.	3.5	18
40	Reply. <i>Arthritis Care and Research</i> , 2018, 70, 168-168.	3.4	1
41	Refinement of the Montreal Instrument for Cat Arthritis Testing, for Use by Veterinarians: detection of naturally occurring osteoarthritis in laboratory cats. <i>Journal of Feline Medicine and Surgery</i> , 2018, 20, 728-740.	1.6	17
42	Diagnostic Validity of Combining History Elements and Physical Examination Tests for Traumatic and Degenerative Symptomatic Meniscal Tears. <i>PM and R</i> , 2018, 10, 472-482.	1.6	5
43	Knee pain as a predictor of structural progression over 4 years: data from the Osteoarthritis Initiative, a prospective cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 250.	3.5	36
44	Initial derivation of diagnostic clusters combining history elements and physical examination tests for symptomatic knee osteoarthritis. <i>Musculoskeletal Care</i> , 2018, 16, 370-379.	1.4	2
45	Impact of oral osteoarthritis therapy usage among other risk factors on knee replacement: a nested case-control study using the Osteoarthritis Initiative cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 172.	3.5	16
46	Clinical diagnosis of partial or complete anterior cruciate ligament tears using patients' history elements and physical examination tests. <i>PLoS ONE</i> , 2018, 13, e0198797.	2.5	19
47	Peak vertical force in a stabilized canine cranial cruciate deficient stifle model: A one-year follow-up. <i>Canadian Journal of Veterinary Research</i> , 2018, 82, 159-161.	0.2	1
48	Spinal neuropeptide modulation, functional assessment and cartilage lesions in a monosodium iodoacetate rat model of osteoarthritis. <i>Neuropeptides</i> , 2017, 65, 56-62.	2.2	12
49	Bone curvature changes can predict the impact of treatment on cartilage volume loss in knee osteoarthritis: data from a 2-year clinical trial. <i>Rheumatology</i> , 2017, 56, 989-998.	1.9	11
50	Exacerbation of Aging-Associated and Instability-Induced Murine Osteoarthritis With Deletion of D Prostanoid Receptor 1, a Prostaglandin D ₂ Receptor. <i>Arthritis and Rheumatology</i> , 2017, 69, 1784-1795.	5.6	11
51	Intra-articular hyaluronic acid in the treatment of knee osteoarthritis: a Canadian evidence-based perspective. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017, 9, 231-246.	2.7	59
52	Levels of serum biomarkers from a two-year multicentre trial are associated with treatment response on knee osteoarthritis cartilage loss as assessed by magnetic resonance imaging: an exploratory study. <i>Arthritis Research and Therapy</i> , 2017, 19, 169.	3.5	30
53	Analgesic efficacy of tramadol in cats with naturally occurring osteoarthritis. <i>PLoS ONE</i> , 2017, 12, e0175565.	2.5	35
54	Analgesic efficacy of an oral transmucosal spray formulation of meloxicam alone or in combination with tramadol in cats with naturally occurring osteoarthritis. <i>Veterinary Anaesthesia and Analgesia</i> , 2016, 43, 643-651.	0.6	34

#	ARTICLE	IF	CITATIONS
55	Long-Term Effects of Glucosamine and Chondroitin Sulfate on the Progression of Structural Changes in Knee Osteoarthritis: Six-Year Followup Data From the Osteoarthritis Initiative. <i>Arthritis Care and Research</i> , 2016, 68, 1560-1566.	3.4	30
56	Correlation Between Changes in Global Knee Structures Assessed by Magnetic Resonance Imaging and Radiographic Osteoarthritis Changes Over Ten Years in a Midlife Cohort. <i>Arthritis Care and Research</i> , 2016, 68, 958-964.	3.4	7
57	Measuring Disease Progression in Osteoarthritis. <i>Current Treatment Options in Rheumatology</i> , 2016, 2, 97-110.	1.4	10
58	Concurrent validity of different functional and neuroproteomic pain assessment methods in the rat osteoarthritis monosodium iodoacetate (MIA) model. <i>Arthritis Research and Therapy</i> , 2016, 18, 150.	3.5	26
59	Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study. <i>Arthritis Research and Therapy</i> , 2016, 18, 256.	3.5	38
60	Osteoarthritis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16072.	30.5	1,011
61	Does cartilage volume measurement or radiographic osteoarthritis at baseline independently predict ten-year cartilage volume loss?. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 54.	1.9	6
62	Natural history and clinical significance of meniscal tears over 8 years in a midlife cohort. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 4.	1.9	20
63	Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 37-44.	0.9	194
64	Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, S22-S27.	3.4	101
65	Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO. <i>Drugs and Aging</i> , 2016, 33, 75-85.	2.7	116
66	A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis: From evidence-based medicine to the real-life setting. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, S3-S11.	3.4	203
67	The levels of the adipokines adipon and leptin are associated with knee osteoarthritis progression as assessed by MRI and incidence of total knee replacement in symptomatic osteoarthritis patients: a post hoc analysis. <i>Rheumatology</i> , 2016, 55, 680-688.	1.9	51
68	Efficacy and safety of topical NSAIDs in the management of osteoarthritis: Evidence from real-life setting trials and surveys. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, S18-S21.	3.4	157
69	Animal models of osteoarthritis. , 2015, , 1454-1461.		4
70	Magnetic Resonance Imaging-Assessed Vastus Medialis Muscle Fat Content and Risk for Knee Osteoarthritis Progression: Relevance From a Clinical Trial. <i>Arthritis Care and Research</i> , 2015, 67, 1406-1415.	3.4	26
71	Discrepancies in Composition and Biological Effects of Different Formulations of Chondroitin Sulfate. <i>Molecules</i> , 2015, 20, 4277-4289.	3.8	84
72	History of knee injury and MRI-assessed knee structures in middle- and older-aged adults: a cross-sectional study. <i>Clinical Rheumatology</i> , 2015, 34, 1463-1472.	2.2	4

#	ARTICLE	IF	CITATIONS
73	Meniscal extrusion promotes knee osteoarthritis structural progression: protective effect of strontium ranelate treatment in a phase III clinical trial. <i>Arthritis Research and Therapy</i> , 2015, 17, 82.	3.5	25
74	Response to: "Concerns about report suggesting glucosamine and chondroitin protect against cartilage loss" by Felson. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e39-e39.	0.9	0
75	PPAR β deficiency results in severe, accelerated osteoarthritis associated with aberrant mTOR signalling in the articular cartilage. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 569-578.	0.9	186
76	Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 422-429.	0.9	106
77	Can We Identify Patients with High Risk of Osteoarthritis Progression Who Will Respond to Treatment? A Focus on Biomarkers and Frailty. <i>Drugs and Aging</i> , 2015, 32, 525-535.	2.7	31
78	Impact of disease treatments on the progression of knee osteoarthritis structural changes related to meniscal extrusion: Data from the OAI progression cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 257-267.	3.4	21
79	[¹⁸ F]-fluorodeoxyglucose positron emission tomography of the cat brain: A feasibility study to investigate osteoarthritis-associated pain. <i>Veterinary Journal</i> , 2015, 204, 299-303.	1.7	19
80	Drug/Agent Treatments for Osteoarthritis: Present and Future. , 2015, , 191-210.		3
81	Coxofemoral joint kinematics using video fluoroscopic images of treadmill-walking cats: development of a technique to assess osteoarthritis-associated disability. <i>Journal of Feline Medicine and Surgery</i> , 2015, 17, 134-143.	1.6	4
82	Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1432-1440.	0.9	322
83	First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 547-556.	0.9	81
84	The presence of meniscal lesions is a strong predictor of neuropathic pain in symptomatic knee osteoarthritis: a cross-sectional pilot study. <i>Arthritis Research and Therapy</i> , 2014, 16, 507.	3.5	50
85	Responsiveness of Magnetic Resonance Imaging-derived Measures Over 2.7 Years. <i>Journal of Rheumatology</i> , 2014, 41, 2060-2067.	2.0	8
86	An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 253-263.	3.4	414
87	A medicinal herb-based natural health product improves the condition of a canine natural osteoarthritis model: A randomized placebo-controlled trial. <i>Research in Veterinary Science</i> , 2014, 97, 574-581.	1.9	19
88	Association between sensitisation and pain-related behaviours in an experimental canine model of osteoarthritis. <i>Pain</i> , 2014, 155, 2071-2079.	4.2	10
89	Evoked Temporal Summation in Cats to Highlight Central Sensitization Related to Osteoarthritis-Associated Chronic Pain: A Preliminary Study. <i>PLoS ONE</i> , 2014, 9, e97347.	2.5	26
90	Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 303-313.	3.4	239

#	ARTICLE	IF	CITATIONS
91	New and emerging treatments for osteoarthritis management: will the dream come true with personalized medicine?. Expert Opinion on Pharmacotherapy, 2013, 14, 2059-2077.	1.8	24
92	Total Knee Replacement as a Knee Osteoarthritis Outcome. Cartilage, 2013, 4, 219-226.	2.7	29
93	Adult Cartilage-Specific Peroxisome Proliferator-Activated Receptor Gamma Knockout Mice Exhibit the Spontaneous Osteoarthritis Phenotype. American Journal of Pathology, 2013, 182, 1099-1106.	3.8	63
94	Strontium ranelate reduces the progression of experimental dog osteoarthritis by inhibiting the expression of key proteases in cartilage and of IL-1 β in the synovium. Annals of the Rheumatic Diseases, 2013, 72, 250-257.	0.9	68
95	A Posteriori Comparison of Natural and Surgical Destabilization Models of Canine Osteoarthritis. BioMed Research International, 2013, 2013, 1-12.	1.9	30
96	Assessment of Cartilage Changes Over Time in Knee Osteoarthritis Disease-Modifying Osteoarthritis Drug Trials Using Semiquantitative and Quantitative Methods: Pros and Cons. Arthritis Care and Research, 2013, 65, 686-694.	3.4	24
97	Expression of Peroxisome Proliferator-activated Receptors $\hat{1}\alpha$, $\hat{1}\beta$, $\hat{1}\gamma$, and H- and L-Prostaglandin D Synthase During Osteoarthritis in the Spontaneous Hartley Guinea Pig and Experimental Dog Models. Journal of Rheumatology, 2013, 40, 877-890.	2.0	17
98	Reliability and sensitivity to change of IW-TSE versus DESS magnetic resonance imaging sequences in the assessment of bone marrow lesions in knee osteoarthritis patients: Longitudinal data from the Osteoarthritis Initiative (OAI) cohort. Journal of Biomedical Science and Engineering, 2013, 06, 337-345.	0.4	5
99	<i>Brachyctenium calycinum</i> D. Don Effectively Reduces the Locomotor Disability in Dogs with Naturally Occurring Osteoarthritis: A Randomized Placebo-Controlled Trial. Evidence-based Complementary and Alternative Medicine, 2012, 2012, 1-9.	1.2	12
100	Influence of Tumor Necrosis Factor $\hat{1}\alpha$, Parathyroid Hormone, and Vitamin D ₃ on Modulation of the RANKL2 Isoform. Cartilage, 2012, 3, 100-103.	2.7	1
101	In vivo bone-specific EphB4 overexpression in mice protects both subchondral bone and cartilage during osteoarthritis. Arthritis and Rheumatism, 2012, 64, 3614-3625.	6.7	31
102	Future therapeutics for osteoarthritis. Bone, 2012, 51, 297-311.	2.9	93
103	Clinical validity of outcome pain measures in naturally occurring canine osteoarthritis. BMC Veterinary Research, 2012, 8, 162.	1.9	42
104	Egr-1 contributes to IL-1-mediated down-regulation of peroxisome proliferator-activated receptor $\hat{1}\gamma$ expression in human osteoarthritic chondrocytes. Arthritis Research and Therapy, 2012, 14, R69.	3.5	25
105	A fully automated system for quantification of knee bone marrow lesions using MRI and the osteoarthritis initiative cohort. Journal of Biomedical Graphics and Computing, 2012, 3, .	0.2	6
106	Egr-1 mediates the suppressive effect of IL-1 on PPAR γ expression in human OA chondrocytes. FASEB Journal, 2012, 26, lb80.	0.5	0
107	Peroxisome proliferator-activated receptor gamma in osteoarthritis. Modern Rheumatology, 2011, 21, 1-9.	1.8	57
108	Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation. Annals of the Rheumatic Diseases, 2011, 70, 1382-1388.	0.9	93

#	ARTICLE	IF	CITATIONS
109	Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. <i>Arthritis Research and Therapy</i> , 2011, 13, R98.	3.5	86
110	Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. <i>Nature Reviews Rheumatology</i> , 2011, 7, 33-42.	8.0	1,973
111	Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts. <i>Bone</i> , 2011, 49, 559-567.	2.9	103
112	A fully automated human knee 3D MRI bone segmentation using the ray casting technique. <i>Medical and Biological Engineering and Computing</i> , 2011, 49, 1413-1424.	2.8	49
113	Treatment with Tiludronic Acid Helps Reduce the Development of Experimental Osteoarthritis Lesions in Dogs with Anterior Cruciate Ligament Transection Followed by Reconstructive Surgery: A 1-Year Study with Quantitative Magnetic Resonance Imaging. <i>Journal of Rheumatology</i> , 2011, 38, 118-128.	2.0	20
114	Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 982-989.	0.9	164
115	Proteinase-activated Receptor-2 Gene Disruption Limits the Effect of Osteoarthritis on Cartilage in Mice: A Novel Target in Joint Degradation. <i>Journal of Rheumatology</i> , 2011, 38, 911-920.	2.0	30
116	Peroxisome proliferator-activated receptor gamma in osteoarthritis. <i>Modern Rheumatology</i> , 2011, 21, 1-9.	1.8	46
117	Animal models of osteoarthritis. , 2011, , 1731-1739.e2.		3
118	Valproic acid suppresses interleukin-1 α -induced microsomal prostaglandin E2 Synthase-1 expression in chondrocytes. <i>FASEB Journal</i> , 2011, 25, 945.14.	0.5	0
119	Prostaglandin D2 enhances interleukin-1 α -induced cyclooxygenase-2 expression in osteoarthritic cartilage. <i>FASEB Journal</i> , 2011, 25, 945.15.	0.5	0
120	Interleukin-1 α -induced cyclooxygenase-2 and inducible nitric oxide synthase expression in human OA chondrocytes is associated with histone H3K4 methylation. <i>FASEB Journal</i> , 2011, 25, 945.4.	0.5	0
121	Automatic Human Knee Cartilage Segmentation From 3-D Magnetic Resonance Images. <i>IEEE Transactions on Biomedical Engineering</i> , 2010, 57, 2699-2711.	4.2	98
122	An Open-Label Pilot Study Evaluating by Magnetic Resonance Imaging the Potential for a Disease-Modifying Effect of Celecoxib Compared to a Modelized Historical Control Cohort in the Treatment of Knee Osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 185-192.	3.4	38
123	Targeting subchondral bone for treating osteoarthritis: what is the evidence?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 51-70.	3.3	147
124	Experimental models of osteoarthritis: usefulness in the development of disease-modifying osteoarthritis drugs/agents. <i>Therapy: Open Access in Clinical Medicine</i> , 2010, 7, 621-634.	0.2	12
125	Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2118-2124.	0.9	58
126	Bone marrow lesions in people with knee osteoarthritis predict progression of disease and joint replacement: a longitudinal study. <i>Rheumatology</i> , 2010, 49, 2413-2419.	1.9	178

#	ARTICLE	IF	CITATIONS
127	Variable Effects of 3 Different Chondroitin Sulfate Compounds on Human Osteoarthritic Cartilage/Chondrocytes: Relevance of Purity and Production Process. <i>Journal of Rheumatology</i> , 2010, 37, 656-664.	2.0	47
128	Meniscal extrusion predicts increases in subchondral bone marrow lesions and bone cysts and expansion of subchondral bone in osteoarthritic knees. <i>Rheumatology</i> , 2010, 49, 997-1004.	1.9	101
129	Oral treatment with a <i>Brachystemma calycinum</i> D don plant extract reduces disease symptoms and the development of cartilage lesions in experimental dog osteoarthritis: inhibition of protease-activated receptor 2. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1179-1184.	0.9	13
130	Effects of diacerein at the molecular level in the osteoarthritis disease process. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2010, 2, 95-104.	2.7	79
131	Bone marrow lesions predict site-specific cartilage defect development and volume loss: a prospective study in older adults. <i>Arthritis Research and Therapy</i> , 2010, 12, R222.	3.5	96
132	Fully automated system for the quantification of human osteoarthritic knee joint effusion volume using magnetic resonance imaging. <i>Arthritis Research and Therapy</i> , 2010, 12, R173.	3.5	35
133	New Perspective in Osteoarthritis: The OPG and RANKL System as a Potential Therapeutic Target?. <i>Keio Journal of Medicine</i> , 2009, 58, 29-40.	1.1	90
134	Imaging in osteoarthritis trials: useful or just expensive?. <i>Nature Clinical Practice Rheumatology</i> , 2009, 5, 76-77.	3.2	2
135	Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis. <i>Rheumatology</i> , 2009, 48, 1482-1490.	1.9	99
136	Altered mineralization of human osteoarthritic osteoblasts is attributable to abnormal type I collagen production. <i>Arthritis and Rheumatism</i> , 2009, 60, 1438-1450.	6.7	130
137	Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13. <i>Arthritis Research and Therapy</i> , 2009, 11, R41.	3.5	84
138	Human articular chondrocytes express 15-lipoxygenase-1 and -2: potential role in osteoarthritis. <i>Arthritis Research and Therapy</i> , 2009, 11, R44.	3.5	28
139	Increased expression of lipocalin-type prostaglandin D2 synthase in osteoarthritic cartilage. <i>Arthritis Research and Therapy</i> , 2009, 10, R146.	3.5	21
140	Proteinase-activated receptor (PAR)-2 activation impacts bone resorptive properties of human osteoarthritic subchondral bone osteoblasts. <i>Bone</i> , 2009, 44, 1143-1150.	2.9	34
141	Inhibition of interleukin-1 β -induced matrix metalloproteinases 1 and 13 production in human osteoarthritic chondrocytes by prostaglandin D ₂ . <i>Arthritis and Rheumatism</i> , 2008, 58, 3530-3540.	6.7	53
142	Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts. <i>Arthritis and Rheumatism</i> , 2008, 58, 3820-3830.	6.7	51
143	Osteophytosis, Subchondral Bone Sclerosis, Joint Effusion and Soft Tissue Thickening in Canine Experimental Stifle Osteoarthritis: Comparison Between 1.5T Magnetic Resonance Imaging and Computed Radiography. <i>Veterinary Surgery</i> , 2008, 37, 166-177.	1.0	53
144	Cartilage in normal and osteoarthritis conditions. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 351-384.	3.3	424

#	ARTICLE	IF	CITATIONS
145	Analysis of the precision and sensitivity to change of different approaches to assess cartilage loss by quantitative MRI in a longitudinal multicentre clinical trial in knee osteoarthritis patients. <i>Arthritis Research and Therapy</i> , 2008, 10, R129.	3.5	34
146	Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. <i>Arthritis Research and Therapy</i> , 2008, 10, R71.	3.5	51
147	Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: Influence of osteotropic factors. <i>Bone</i> , 2008, 43, 284-291.	2.9	55
148	Use of Quantitative Magnetic Resonance Imaging in the Cross-Sectional and Longitudinal Evaluation of Structural Changes in Knee Osteoarthritis Patients. , 2008, , 235-248.		2
149	Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. <i>Arthritis Research and Therapy</i> , 2007, 9, R117.	3.5	90
150	Activation of proteinase-activated receptor 2 in human osteoarthritic cartilage upregulates catabolic and proinflammatory pathways capable of inducing cartilage degradation: a basic science study. <i>Arthritis Research and Therapy</i> , 2007, 9, R121.	3.5	61
151	Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study. <i>Arthritis Research and Therapy</i> , 2007, 9, R74.	3.5	204
152	Extracellular localization of galectin-3 has a deleterious role in joint tissues. <i>Arthritis Research and Therapy</i> , 2007, 9, R20.	3.5	38
153	The peroxisome proliferator-activated receptor γ agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: In vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. <i>Arthritis and Rheumatism</i> , 2007, 56, 2288-2298.	6.7	68
154	Meniscal tear as an osteoarthritis risk factor in a largely non-osteoarthritic cohort: a cross-sectional study. <i>Journal of Rheumatology</i> , 2007, 34, 776-84.	2.0	115
155	DMOAD developments: present and future. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2007, 65, 242-8.	0.7	27
156	Abnormal insulin-like growth factor 1 signaling in human osteoarthritic subchondral bone osteoblasts. <i>Arthritis Research and Therapy</i> , 2006, 8, R177.	3.5	42
157	Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow. <i>Arthritis Research and Therapy</i> , 2006, 8, 206.	3.5	55
158	Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. <i>Bone</i> , 2006, 38, 333-341.	2.9	56
159	Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two-year multinational knee osteoarthritis structural arthritis study. <i>Arthritis and Rheumatism</i> , 2006, 54, 3494-3507.	6.7	338
160	Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity. <i>Journal of Rheumatology</i> , 2006, 33, 1176-83.	2.0	16
161	Pioglitazone, a peroxisome proliferator-activated receptor γ agonist, reduces the progression of experimental osteoarthritis in guinea pigs. <i>Arthritis and Rheumatism</i> , 2005, 52, 479-487.	6.7	104
162	Oral treatment with PD-0200347, an α 2 β 1 ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes. <i>Arthritis and Rheumatism</i> , 2005, 52, 488-500.	6.7	59

#	ARTICLE	IF	CITATIONS
163	Osteoarthritis: A metabolic disease induced by local abnormal leptin activity?. <i>Current Rheumatology Reports</i> , 2005, 7, 1-3.	4.7	22
164	Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. <i>Arthritis Research and Therapy</i> , 2005, 8, R21.	3.5	205
165	The protective effect of licofelone on experimental osteoarthritis is correlated with the downregulation of gene expression and protein synthesis of several major cartilage catabolic factors: MMP-13, cathepsin K and aggrecanases. <i>Arthritis Research and Therapy</i> , 2005, 7, R1091.	3.5	56
166	Leukotriene and prostaglandin synthesis pathways in osteoarthritic synovial membranes: regulating factors for interleukin 1beta synthesis. <i>Journal of Rheumatology</i> , 2005, 32, 704-12.	2.0	31
167	Activation of Peroxisome Proliferator-activated Receptor δ Inhibits Interleukin-1 β -induced Membrane-associated Prostaglandin E2 Synthase-1 Expression in Human Synovial Fibroblasts by Interfering with Egr-1. <i>Journal of Biological Chemistry</i> , 2004, 279, 22057-22065.	3.4	100
168	Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2004, 12, 63-68.	1.3	21
169	New Trends in the Treatment of Osteoarthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 34, 13-14.	3.4	5
170	Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes. <i>Arthritis and Rheumatism</i> , 2004, 50, 476-487.	6.7	235
171	Differential gene expression and regulation of the bone morphogenetic protein antagonists follistatin and gremlin in normal and osteoarthritic human chondrocytes and synovial fibroblasts. <i>Arthritis and Rheumatism</i> , 2004, 50, 2521-2530.	6.7	83
172	Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B4 in osteoarthritic chondrocytes: Role of transforming growth factor β and eicosanoids. <i>Arthritis and Rheumatism</i> , 2004, 50, 3925-3933.	6.7	56
173	The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. <i>Bone</i> , 2004, 34, 527-538.	2.9	143
174	Computer-aided method for quantification of cartilage thickness and volume changes using mri: validation study using a synthetic model. <i>IEEE Transactions on Biomedical Engineering</i> , 2003, 50, 978-988.	4.2	134
175	Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2003, 48, 370-377.	6.7	452
176	In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. <i>Arthritis and Rheumatism</i> , 2003, 48, 1582-1593.	6.7	112
177	Oncostatin M: Foe or friend?. <i>Arthritis and Rheumatism</i> , 2003, 48, 3301-3303.	6.7	24
178	The Novartis-ILAR Rheumatology Prize 2001 Osteoarthritis: from molecule to man. <i>Arthritis Research</i> , 2002, 4, 13.	2.0	9
179	Study of the role of leukotriene B4 in abnormal function of human subchondral osteoarthritis osteoblasts: Effects of cyclooxygenase and/or 5-lipoxygenase inhibition. <i>Arthritis and Rheumatism</i> , 2002, 46, 1804-1812.	6.7	64
180	The in situ up-regulation of chondrocyte interleukin-1-converting enzyme and interleukin-18 levels in experimental osteoarthritis is mediated by nitric oxide. <i>Arthritis and Rheumatism</i> , 2002, 46, 2637-2647.	6.7	64

#	ARTICLE	IF	CITATIONS
181	PPARgamma ligands as modulators of inflammatory and catabolic responses in arthritis. An overview. <i>Journal of Rheumatology</i> , 2002, 29, 3-14.	2.0	182
182	Synthesis of interleukin 1beta, tumor necrosis factor-alpha, and interstitial collagenase (MMP-1) is eicosanoid dependent in human osteoarthritis synovial membrane explants: interactions with antiinflammatory cytokines. <i>Journal of Rheumatology</i> , 2002, 29, 546-53.	2.0	52
183	Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors. <i>Journal of Rheumatology</i> , 2002, 29, 1446-53.	2.0	27
184	Metalloproteases and inhibitors in arthritic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2001, 15, 805-829.	3.3	233
185	Peroxisome proliferator-activated receptor γ activators inhibit interleukin-1 γ -induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. <i>Arthritis and Rheumatism</i> , 2001, 44, 595-607.	6.7	196
186	Osteoarthritis, an inflammatory disease: Potential implication for the selection of new therapeutic targets. <i>Arthritis and Rheumatism</i> , 2001, 44, 1237-1247.	6.7	953
187	In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: Suppression of collagenase 1 and interleukin-1 γ synthesis. <i>Arthritis and Rheumatism</i> , 2001, 44, 2320-2330.	6.7	100
188	Endogenous Prostaglandin E2 and Insulin-like Growth Factor 1 Can Modulate the Levels of Parathyroid Hormone Receptor in Human Osteoarthritic Osteoblasts. <i>Journal of Bone and Mineral Research</i> , 2001, 16, 713-721.	2.8	59
189	Gene Therapy for Osteoarthritis. <i>Clinical Orthopaedics and Related Research</i> , 2000, 379, S262-S272.	1.5	17
190	Selective inhibition of inducible nitric oxide synthase reduces progression of experimental osteoarthritis in vivo: Possible link with the reduction in chondrocyte apoptosis and caspase 3 level. <i>Arthritis and Rheumatism</i> , 2000, 43, 1290-1299.	6.7	217
191	Efficacy and safety of diacerein in osteoarthritis of the knee: A double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2000, 43, 2339-2348.	6.7	147
192	The Induction of Cell Death in Human Osteoarthritis Chondrocytes by Nitric Oxide Is Related to the Production of Prostaglandin E2 Via the Induction of Cyclooxygenase-2. <i>Journal of Immunology</i> , 2000, 165, 3402-3410.	0.8	171
193	The influence of tissular cross-talking on osteoarthritis progression: role of nonsteroidal antiinflammatory drugs. <i>Osteoarthritis and Cartilage</i> , 1999, 7, 306-307.	1.3	2
194	Subchondral bone morphological and biochemical alterations in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 1999, 7, 321-322.	1.3	48
195	Carprofen reduces the structural changes and the abnormal subchondral bone metabolism of experimental osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 1999, 7, 327-328.	1.3	13
196	Collagenase 3 production by human osteoarthritic chondrocytes in response to growth factors and cytokines is a function of the physiologic state of the cells. <i>Arthritis and Rheumatism</i> , 1999, 42, 1147-1158.	6.7	82
197	Interleukin-1 γ -converting enzyme/caspase-1 in human osteoarthritic tissues: Localization and role in the maturation of interleukin-1 γ and interleukin-18. <i>Arthritis and Rheumatism</i> , 1999, 42, 1577-1587.	6.7	126
198	Abnormal regulation of urokinase plasminogen activator by insulin-like growth factor 1 in human osteoarthritic subchondral osteoblasts. <i>Arthritis and Rheumatism</i> , 1999, 42, 2112-2122.	6.7	58

#	ARTICLE	IF	CITATIONS
199	Mitogen-activated protein kinase and nuclear factor κ B together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes: Possible role of transactivating factor mitogen-activated protein kinase-activated protein kinase (MAPKAPK). <i>Arthritis and Rheumatism</i> , 1999, 42, 2399-2409.	6.7	152
200	In Vivo Transfer of Interleukin-1 Receptor Antagonist Gene in Osteoarthritic Rabbit Knee Joints. <i>American Journal of Pathology</i> , 1999, 154, 1159-1169.	3.8	218
201	Osteoblast-like cells from human subchondral osteoarthritic bone demonstrate an altered phenotype in vitro: Possible role in subchondral bone sclerosis. <i>Arthritis and Rheumatism</i> , 1998, 41, 891-899.	6.7	189
202	Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. <i>Arthritis and Rheumatism</i> , 1998, 41, 1275-1286.	6.7	318
203	Exercise protects against articular cartilage degeneration in the hamster. <i>Arthritis and Rheumatism</i> , 1998, 41, 2068-2076.	6.7	118
204	Transcriptional induction of cyclooxygenase-2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: Co-stimulation of AP-1 and CRE nuclear binding proteins. <i>Journal of Cellular Biochemistry</i> , 1998, 69, 392-413.	2.6	81
205	Transcriptional induction of cyclooxygenase-2 gene by okadaic acid inhibition of phosphatase activity in human chondrocytes: Co-stimulation of AP-1 and CRE nuclear binding proteins. <i>Journal of Cellular Biochemistry</i> , 1998, 69, 392-413.	2.6	4
206	Exercise protects against articular cartilage degeneration in the hamster. <i>Arthritis and Rheumatism</i> , 1998, 41, 2068-2076.	6.7	1
207	Osteoarthritis of the Knee: Report of a Task Force of the International League of Associations for Rheumatology and the Osteoarthritis Research Society. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 850-852.	2.6	4
208	Cloning, sequencing and characterization of the 5'-flanking region of the human collagenase-3 gene. <i>Biochemical Journal</i> , 1997, 323, 13-16.	3.7	63
209	Effects of tenidap on the progression of osteoarthritic lesions in a canine experimental model. Suppression of metalloprotease and interleukin-1 activity. <i>Arthritis and Rheumatism</i> , 1997, 40, 284-294.	6.7	28
210	In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. <i>Arthritis and Rheumatism</i> , 1997, 40, 1012-1019.	6.7	353
211	Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ. In vitro mimicking effect by transforming growth factor β 2. <i>Arthritis and Rheumatism</i> , 1997, 40, 1653-1661.	6.7	163
212	MODULATION OF THE EXPRESSION OF GLUCOCORTICOID RECEPTORS IN SYNOVIAL FIBROBLASTS AND CHONDROCYTES BY PROSTAGLANDINS AND NSAIDs. <i>American Journal of Therapeutics</i> , 1996, 3, 115-119.	0.9	3
213	IGF and IGF-binding protein system in the synovial fluid of osteoarthritic and rheumatoid arthritic patients. <i>Osteoarthritis and Cartilage</i> , 1996, 4, 263-274.	1.3	63
214	The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. <i>Osteoarthritis and Cartilage</i> , 1996, 4, 77-84.	1.3	155
215	Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA is constitutively expressed in bovine, human normal, and osteoarthritic articular chondrocytes. , 1996, 60, 211-217.		40
216	Normal expression of type 1 insulin-like growth factor receptor by human osteoarthritic chondrocytes with increased expression and synthesis of insulin-like growth factor binding proteins. <i>Arthritis and Rheumatism</i> , 1996, 39, 968-978.	6.7	78

#	ARTICLE	IF	CITATIONS
217	Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. <i>Arthritis and Rheumatism</i> , 1996, 39, 1535-1544.	6.7	338
218	Increased insulin-like growth factor 1 production by human osteoarthritic chondrocytes is not dependent on growth hormone action. <i>Arthritis and Rheumatism</i> , 1995, 38, 413-419.	6.7	33
219	Effects of tenidap on canine experimental osteoarthritis i. morphologic and metalloprotease analysis. <i>Arthritis and Rheumatism</i> , 1995, 38, 1290-1303.	6.7	58
220	Interleukin-1 β induction of tissue inhibitor of metalloproteinase (TIMP-1) is functionally antagonized by prostaglandin E2 in human synovial fibroblasts. <i>Journal of Cellular Biochemistry</i> , 1995, 57, 619-629.	2.6	18
221	Human Osteoarthritic Chondrocytes Possess an Increased Number of Insulin-Like Growth Factor 1 Binding Sites but are Unresponsive to its Stimulation. <i>Arthritis and Rheumatism</i> , 1994, 37, 253-263.	6.7	186
222	Intraarticular Injections with Methylprednisolone Acetate Reduce Osteoarthritic Lesions in Parallel with Chondrocyte Stromelysin Synthesis in Experimental Osteoarthritis. <i>Arthritis and Rheumatism</i> , 1994, 37, 414-423.	6.7	122
223	Transcriptional regulation of plasminogen activator inhibitor-1 expression in human synovial fibroblasts by prostaglandin E2: mediation by protein kinase A and role of interleukin-1. <i>Molecular and Cellular Endocrinology</i> , 1994, 103, 139-148.	3.2	12
224	Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. <i>Arthritis and Rheumatism</i> , 1993, 36, 1517-1527.	6.7	42
225	Effects of Nimesulide and Naproxen on the Degradation and Metalloprotease Synthesis of Human Osteoarthritic Cartilage. <i>Drugs</i> , 1993, 46, 34-39.	10.9	46
226	The synthesis of IL-1 receptor antagonist (IL-1ra) by synovial fibroblasts is markedly increased by the cytokines TNF- α and IL-1. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1993, 1175, 302-305.	4.1	28
227	In Vitro Effects of NSAIDS and Corticosteroids on the Synthesis and Secretion of Interleukin 1 by Human Osteoarthritic Synovial Membranes. , 1993, 39, 181-193.		13
228	Expression of c-fos, c-jun, jun-B, metallothionein and metalloproteinase genes in human chondrocyte. <i>FEBS Letters</i> , 1992, 306, 169-172.	2.8	39
229	The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. <i>Arthritis and Rheumatism</i> , 1992, 35, 530-540.	6.7	151
230	Immunological analysis of proteoglycan structural changes in the early stage of experimental osteoarthritic canine cartilage lesions. <i>Journal of Orthopaedic Research</i> , 1992, 10, 511-523.	2.3	30
231	Synovial membrane histology and immunopathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs. <i>Arthritis and Rheumatism</i> , 1991, 34, 153-163.	6.7	156
232	Glucocorticoid Receptor Mediated Inhibition of Interleukin-1 Stimulated Neutral Metalloprotease Synthesis in Normal Human Chondrocytes*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1991, 72, 316-326.	3.6	77
233	Imbalance between the mechanisms of activation and inhibition of metalloproteases in the early lesions of experimental osteoarthritis. <i>Arthritis and Rheumatism</i> , 1990, 33, 1466-1476.	6.7	126
234	Protective effects of corticosteroids on cartilage lesions and osteophyte formation in the pond-nuki dog model of osteoarthritis. <i>Arthritis and Rheumatism</i> , 1989, 32, 181-193.	6.7	156

#	ARTICLE	IF	CITATIONS
235	Human rheumatoid arthritic cartilage and its neutral proteoglycan-degrading proteases. The effects of antirheumatic drugs. <i>Arthritis and Rheumatism</i> , 1985, 28, 405-412.	6.7	23
236	Role of synovial membrane inflammation in cartilage matrix breakdown in the Pond-Nuki dog model of osteoarthritis. <i>Arthritis and Rheumatism</i> , 1985, 28, 554-561.	6.7	120
237	Cartilage degradation by neutral proteoglycanases in experimental osteoarthritis. Suppression by steroids. <i>Arthritis and Rheumatism</i> , 1985, 28, 1393-1401.	6.7	51
238	Ntp pyrophosphohydrolase in human chondrocalcinotic and osteoarthritic cartilage: some biochemical characteristic. <i>Arthritis and Rheumatism</i> , 1984, 27, 186-192.	6.7	38
239	Ntp pyrophosphohydrolase in human chondrocalcinotic and osteoarthritic cartilage: Further Studies on Histologic and Subcellular Distribution. <i>Arthritis and Rheumatism</i> , 1984, 27, 193-199.	6.7	56
240	Neutral proteases capable of proteoglycan digesting activity in osteoarthritic and normal human articular cartilage. <i>Arthritis and Rheumatism</i> , 1984, 27, 305-312.	6.7	156
241	Collagenase and collagenolytic activity in human osteoarthritic cartilage. <i>Arthritis and Rheumatism</i> , 1983, 26, 63-68.	6.7	152
242	Collagenolytic activity and collagen matrix breakdown of the articular cartilage in the pond-nuki dog model of osteoarthritis. <i>Arthritis and Rheumatism</i> , 1983, 26, 866-874.	6.7	124
243	Metalloproteases and Their Modulation as Treatment in Osteoarthritis. , 0, , 499-513.		4